Literature DB >> 9210064

Focal dystonia after chemotherapy: a case series.

A Brashear1, E Siemers.   

Abstract

Dystonia is a rare neurologic disorder of the basal ganglia presenting with involuntary twisting or turning spasm of muscles. Movements localized to the face, eyes, or neck generally present during late adulthood. Cranial dystonia is usually idiopathic but may be caused by trauma or medications. Of 148 patients with focal dystonia referred to Indiana University over four years, four women had the onset of face and neck symptoms eight days to 34 months after completing treatment with chemotherapy alone or combined with radiation therapy. Two patients were treated with 5-FU, one received doxorubicin and one was treated with both. Both drugs have been associated with transient parkinsonism, but no chemotherapeutic medications have been reported to cause dystonia. Three patients remain free of demonstrable malignancy. A possible association of chemotherapy and focal dystonia has not been previously described.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9210064     DOI: 10.1023/a:1005791623733

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.

Authors:  J L RIEHL; W J BROWN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

2.  Acute dystonia and fluoxetine.

Authors:  B Black; T W Uhde
Journal:  J Clin Psychiatry       Date:  1992-09       Impact factor: 4.384

3.  Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.

Authors:  B E Harris; J T Carpenter; R B Diasio
Journal:  Cancer       Date:  1991-08-01       Impact factor: 6.860

4.  Natural history of idiopathic torsion dystonia.

Authors:  C D Marsden; M J Harrison; S Bundey
Journal:  Adv Neurol       Date:  1976

Review 5.  Dopaminergic mechanisms in cranial dystonia.

Authors:  E Tolosa; J Kulisevsky
Journal:  Adv Neurol       Date:  1988

Review 6.  Autoimmune central nervous system paraneoplastic disorders: mechanisms, diagnosis, and therapeutic options.

Authors:  E J Dropcho
Journal:  Ann Neurol       Date:  1995-05       Impact factor: 10.422

7.  Time course of postanoxic akinetic-rigid and dystonic syndromes.

Authors:  M H Bhatt; J A Obeso; C D Marsden
Journal:  Neurology       Date:  1993-02       Impact factor: 9.910

8.  Multifocal inflammatory leukoencephalopathy associated with levamisole therapy.

Authors:  D W Kimmel; E F Wijdicks; M Rodriguez
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

9.  Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.

Authors:  P A Ballard; J W Tetrud; J W Langston
Journal:  Neurology       Date:  1985-07       Impact factor: 9.910

10.  Parkinsonism induced by high-dose cytosine arabinoside.

Authors:  F A Luque; J B Selhorst; P Petruska
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

View more
  4 in total

Review 1.  Neurologic complications of chemotherapy for children with cancer.

Authors:  Alyssa T Reddy; Kerry Witek
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

Review 2.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

3.  Oromandibular dystonia: a serious side effect of capecitabine.

Authors:  Melanie J M van Pelt-Sprangers; Eric C T Geijteman; Jelmer Alsma; Ingrid A Boere; Ron H J Mathijssen; Stephanie C E Schuit
Journal:  BMC Cancer       Date:  2015-03-11       Impact factor: 4.430

4.  Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes.

Authors:  Eng Wee Chua; Simon P Harger; Martin A Kennedy
Journal:  Front Pharmacol       Date:  2019-08-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.